بحث بسيط
السجلات المعروضة 1 -- 10 من 40
Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals
(
MDPI
, 2020 , Article)
Abstract: To support the deployment of serology assays for population screening during the
COVID-19 pandemic, we compared the performance of three fully automated SARS-CoV-2 IgG assays: Mindray CL-900i® (target: spike [S] ...
Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies
(
Elsevier
, 2020 , Article)
ObjectivesTo evaluate and compare the performances of five commercial ELISA assays (EDI, AnshLabs, Dia.Pro, NovaTec, and Lionex) for detecting anti-SARS-CoV-2 IgG. Methods70 negative control samples (collected before the ...
Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020
(
BMJ Publishing Group
, 2020 , Article)
© Authors 2020 Objective To define the epidemiological curve of COVID-19 in Qatar and determine factors associated with severe or critical illness. Design Case series of first 5685 COVID-19 cases in Qatar. Setting and ...
Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020
(
Elsevier
, 2021 , Article)
We aimed to estimate, albeit crudely and provisionally, national, regional, and global proportions of respective populations that have been infected with SARS-CoV-2 in the first year after the introduction of this virus ...
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
(
Nature Research
, 2021 , Article)
The SARS-CoV-2 pandemic resulted in considerable morbidity and mortality as well as severe economic and societal disruptions. Despite scientific progress, true infection severity, factoring both diagnosed and undiagnosed ...
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
(
Elsevier
, 2022 , Article)
ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe ...
All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
(
BMJ Publishing Group
, 2023 , Article)
Objective To investigate all-cause mortality, COVID-19 mortality and all-cause non-COVID-19 mortality in Qatar during the COVID-19 pandemic. Methods A national, retrospective cohort analysis and national, matched, retrospective ...
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
(
Nature Research
, 2022 , Article)
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...
Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
(
MDPI
, 2022 , Report)
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was ...
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient
(
Elsevier
, 2024 , Article)
BackgroundVaccines were developed and deployed to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to characterize patterns in the protection provided by the BNT162b2 and ...